GlassScriptPhysician profile
Timothy L Gillison
NPI 1710905906
$1,051.88
in general payments reported to CMS, 2019-2025
21 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2.21 · 2020: $16.57 · 2021: $23.32 · 2022: $46.44 · 2023: $110 · 2024: $706 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $812 · Education: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $811.74 |
| Education | $151.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $160.29 | 2023-2025 | Tecvayli, Talvey, Darzalex |
| Gilead Sciences, INC. | $157.97 | 2021-2025 | Trodelvy |
| Incyte Corporation | $99.95 | 2024 | |
| Aveo Pharmaceuticals, INC. | $98.44 | 2022-2024 | Fotivda |
| Astellas Pharma US INC | $82.65 | 2024 | Vyloy, Xospata |
| Astrazeneca Pharmaceuticals LP | $51.42 | 2024 | Imfinzi |
| Pfizer INC. | $46.09 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $38.81 | 2020-2025 | Opdualag |
| Jazz Pharmaceuticals INC. | $35.57 | 2024 | |
| Mirati Therapeutics, INC. | $35.31 | 2023 | Krazati |
| Array Biopharma INC | $34.83 | 2024-2025 | Xalkori, Lorbrena, Braftovi |
| Genentech USA, INC. | $32.83 | 2024 | Tecentriq, Alecensa, Rozlytrek |
| Takeda Pharmaceuticals U.S.A., INC. | $28.01 | 2025 | Fruzaqla |
| Novartis Pharmaceuticals Corporation | $27.60 | 2023-2024 | |
| Emd Serono, INC. | $25.37 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $25.31 | 2024 | Darzalex |
| Merck Sharp & Dohme LLC | $22.76 | 2024 | Keytruda, Welireg |
| Abbvie INC. | $19.57 | 2024 | |
| Celgene Corporation | $15.49 | 2024 | Reblozyl |
| Adc Therapeutics America, INC. | $11.40 | 2021 | |
| Clovis Oncology, INC. | $2.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Gillison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.